Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence.
Elisabetta SignorielloGiacomo LusFrancesco SaccàMarco PuthenparampilCinzia CoppolaAndrea Di PietroGianfranco PuotiMaria Cristina CriscuoloMatteo FoschiGiuseppina MieleGianmarco AbbadessaVincenzo Brescia MorraPaolo GalloSimona BonavitaMaria Pia SormaniAlessio SignoriPublished in: Journal of clinical medicine (2023)
Our real-world study supports data from clinical trials in which lymphocyte subsets were not useful for predicting disease activity or autoimmune disease during treatment. The early use of an induction therapy such as alemtuzumab in patients with a lower EDSS score and short history of disease could mitigate the risk of treatment failure.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- clinical trial
- peripheral blood
- juvenile idiopathic arthritis
- multiple sclerosis
- stem cells
- electronic health record
- randomized controlled trial
- combination therapy
- big data
- data analysis
- deep learning
- phase ii
- study protocol